Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

Phase 4 Completed 120 enrolled Sinovac Biotech Co., Ltd Shangyu District Center for Disease Control and Prevention · collab Zhejiang Provincial Center for Disease Control and Prevention · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different time after vaccination

Timeline

Start: 2017-07-16
Primary completion: 2017-09-15
Completion: 2017-09-15

Publications

Wang S, Zeng J, Zhang X, Gan Z, Fan J, Chen Y, Liang Z, Hu X, Zeng G, Lv H. Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination. Hum Vaccin Immunother. 2020 Jul 2;16(7):1595-1601. doi: 10.1080/21645515.2020.1711678. Epub 2020 Jan 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EV71 vaccine	Vaccine	0.5 ml	Intramuscular

Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

Summary

Timeline

Publications

Drugs

Indications